Relmada Therapeutics (RLMD)

• Market cap: $11.1M
• 1 day: 1.49%
• 5 days: -2.33%
• 1 month: -86.66%
• 3 months: -89.48%
• 6 months: -87.72%
• Year to date: -91.57%
• 1 year: -88.77%
• 5 years: -99.13%
• 10 years: -96.64%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Employees: 20

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

222% more call options, than puts

Call options by funds: $1.67M | Put options by funds: $520K

1% less capital invested

Capital invested by funds: $40.8M [Q2] → $40.2M (-$574K) [Q3]

4.06% less ownership

Funds ownership: 45.09% [Q2] → 41.02% (-4.06%) [Q3]

13% less funds holding

Funds holding: 79 [Q2] → 69 (-10) [Q3]

56% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 25

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 172% upside
• Avg. target: $1 172% upside
• High target: $1 172% upside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

Mizuho Uy Ear 50% 1-year accuracy 6 / 12 met price target	172% upside $1	Neutral Downgraded	5 Dec 2024
Leerink Partners Marc Goodman 50% 1-year accuracy 1 / 2 met price target	172% upside $1	Market Perform Downgraded	4 Dec 2024